Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography.

Meyer PF, Binette AP, Gonneaud J, Breitner JCS, Villeneuve S.

JAMA Neurol. 2020 Jan 21. doi: 10.1001/jamaneurol.2019.4749. [Epub ahead of print]

PMID:
31961372
2.

MR-based age-related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan.

Tullo S, Patel R, Devenyi GA, Salaciak A, Bedford SA, Farzin S, Wlodarski N, Tardif CL; PREVENT-AD Research Group, Breitner JCS, Chakravarty MM.

Hum Brain Mapp. 2019 Dec 15;40(18):5269-5288. doi: 10.1002/hbm.24771. Epub 2019 Aug 26.

PMID:
31452289
3.

Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.

Meyer PF, Savard M, Poirier J, Morgan D, Breitner J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Sep;15(9):1160-1171. doi: 10.1016/j.jalz.2019.05.007. Epub 2019 Aug 9.

4.

Association of PPP2R1A with Alzheimer's disease and specific cognitive domains.

Miron J, Picard C, Labonté A, Auld D, Breitner J, Poirier J; United Kingdom Brain Expression Consortium; PREVENT-AD research group.

Neurobiol Aging. 2019 Sep;81:234-243. doi: 10.1016/j.neurobiolaging.2019.06.008. Epub 2019 Jul 2.

PMID:
31349112
5.

No apparent effect of naproxen on CSF markers of innate immune activation.

Meyer PF, Labonté A, Rosa-Neto P, Poirier J, Breitner JCS; PREVENT‐AD Research Group.

Ann Clin Transl Neurol. 2019 Jun 6;6(6):1127-1133. doi: 10.1002/acn3.788. eCollection 2019 Jun.

6.

Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation.

Miron J, Picard C, Lafaille-Magnan MÉ, Savard M, Labonté A, Breitner J, Rosa-Neto P, Auld D, Poirier J; PREVENT-AD research group.

Alzheimers Dement. 2019 Jul;15(7):951-960. doi: 10.1016/j.jalz.2019.03.012. Epub 2019 Jun 4.

PMID:
31175027
7.

Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression.

Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G.

Nat Commun. 2019 May 20;10(1):2240. doi: 10.1038/s41467-019-10152-w.

8.

A highly predictive signature of cognition and brain atrophy for progression to Alzheimer's dementia.

Tam A, Dansereau C, Iturria-Medina Y, Urchs S, Orban P, Sharmarke H, Breitner J, Bellec P; Alzheimer's Disease Neuroimaging Initiative.

Gigascience. 2019 May 1;8(5). pii: giz055. doi: 10.1093/gigascience/giz055.

9.

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.

Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan MÉ, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner J; PREVENT-AD Research Group.

Neurology. 2019 Apr 30;92(18):e2070-e2080. doi: 10.1212/WNL.0000000000007232. Epub 2019 Apr 5. Erratum in: Neurology. 2019 Aug 20;93(8):371.

10.

The Telephone Interview for Cognitive Status.

Breitner JCS.

Cogn Behav Neurol. 2018 Sep;31(3):159. doi: 10.1097/WNN.0000000000000167. No abstract available.

PMID:
30239468
11.

Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease.

Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 May;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012. Epub 2017 Dec 14.

PMID:
29735156
12.

Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease.

Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative* and the PREVENT-AD Research Group.

Brain. 2018 Jun 1;141(6):1871-1883. doi: 10.1093/brain/awy093.

13.

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.

Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, Town T, Breitner J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group.

J Alzheimers Dis. 2018;63(2):577-590. doi: 10.3233/JAD-170887.

14.

Alterations in cholesterol metabolism-related genes in sporadic Alzheimer's disease.

Picard C, Julien C, Frappier J, Miron J, Théroux L, Dea D; United Kingdom Brain Expression Consortium and for the Alzheimer's Disease Neuroimaging Initiative, Breitner JCS, Poirier J.

Neurobiol Aging. 2018 Jun;66:180.e1-180.e9. doi: 10.1016/j.neurobiolaging.2018.01.018. Epub 2018 Feb 9.

PMID:
29503034
15.

Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.

Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.

JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135.

16.

Author response: Odor identification as a biomarker of preclinical AD in older adults at risk.

Lafaille-Magnan ME, Breitner JCS.

Neurology. 2018 Feb 13;90(7):343. doi: 10.1212/WNL.0000000000004959. No abstract available.

PMID:
29440548
17.

Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer's Disease.

Konishi K, Joober R, Poirier J, MacDonald K, Chakravarty M, Patel R, Breitner J, Bohbot VD.

J Alzheimers Dis. 2018;61(4):1493-1507. doi: 10.3233/JAD-170540.

18.

EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.

Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, Gauthier S, Grundman M, Hendrix S, Ho C, Isaac M, Raman R, Rosenberg P, Schindler R, Schneider L, Sperling R, Tariot P, Welsh-Bohmer K, Weiner M, Vellas B.

J Prev Alzheimers Dis. 2017;4(2):116-124. doi: 10.14283/jpad.2017.13.

19.

Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.

Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner J, Chakravarty MM; PREVENT-AD Research Group.

Hum Brain Mapp. 2018 Feb;39(2):971-984. doi: 10.1002/hbm.23897. Epub 2017 Nov 21.

PMID:
29164798
20.

Dendritic Polyglycerol Sulfates in the Prevention of Synaptic Loss and Mechanism of Action on Glia.

Maysinger D, Ji J, Moquin A, Hossain S, Hancock MA, Zhang I, Chang PKY, Rigby M, Anthonisen M, Grütter P, Breitner J, McKinney RA, Reimann S, Haag R, Multhaup G.

ACS Chem Neurosci. 2018 Feb 21;9(2):260-271. doi: 10.1021/acschemneuro.7b00301. Epub 2017 Nov 10.

PMID:
29078046
21.

Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.

Tuwaig M, Savard M, Jutras B, Poirier J, Collins DL, Rosa-Neto P, Fontaine D, Breitner JCS; PREVENT-AD Research Group.

J Alzheimers Dis. 2017;60(4):1589-1600. doi: 10.3233/JAD-170545.

22.

Odor identification as a biomarker of preclinical AD in older adults at risk.

Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS; PREVENT-AD Research Group.

Neurology. 2017 Jul 25;89(4):327-335. doi: 10.1212/WNL.0000000000004159. Epub 2017 Jun 28.

23.

Dementia registries around the globe and their applications: A systematic review.

Krysinska K, Sachdev PS, Breitner J, Kivipelto M, Kukull W, Brodaty H.

Alzheimers Dement. 2017 Sep;13(9):1031-1047. doi: 10.1016/j.jalz.2017.04.005. Epub 2017 May 30. Review.

24.

Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease.

Dadar M, Pascoal TA, Manitsirikul S, Misquitta K, Fonov VS, Tartaglia MC, Breitner J, Rosa-Neto P, Carmichael OT, Decarli C, Collins DL.

IEEE Trans Med Imaging. 2017 Aug;36(8):1758-1768. doi: 10.1109/TMI.2017.2693978. Epub 2017 Apr 12.

PMID:
28422655
25.

Comment: MCI trials-Categorical "square pegs" in dimensional "round holes"?

Breitner JCS.

Neurology. 2017 May 2;88(18):1757. doi: 10.1212/WNL.0000000000003893. Epub 2017 Apr 5. No abstract available.

PMID:
28381505
26.

A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment.

Tam A, Dansereau C, Badhwar A, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P, Shmuel A, Breitner J, Bellec P; Alzheimer׳s Disease Neuroimaging Initiative.

Data Brief. 2016 Nov 18;9:1122-1129. eCollection 2016 Dec.

27.

Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimer's disease model.

Cavanagh C, Tse YC, Nguyen HB, Krantic S, Breitner JC, Quirion R, Wong TP.

Neurobiol Aging. 2016 Nov;47:41-49. doi: 10.1016/j.neurobiolaging.2016.07.009. Epub 2016 Jul 25.

28.

How can we really improve screening methods for AD prevention trials?

Breitner JCS.

Alzheimers Dement (N Y). 2016 Feb 2;2(1):45-47. doi: 10.1016/j.trci.2015.12.004. eCollection 2016 Jan. Review. No abstract available.

29.

Common Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies.

Tam A, Dansereau C, Badhwar A, Orban P, Belleville S, Chertkow H, Dagher A, Hanganu A, Monchi O, Rosa-Neto P, Shmuel A, Wang S, Breitner J, Bellec P; Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci. 2015 Dec 24;7:242. doi: 10.3389/fnagi.2015.00242. eCollection 2015.

30.

Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD).

Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM.

J Prev Alzheimers Dis. 2016;3(4):236-242. doi: 10.14283/jpad.2016.121.

PMID:
29199324
31.

'Alzheimer's Progression Score': Development of a Biomarker Summary Outcome for AD Prevention Trials.

Leoutsakos JM, Gross AL, Jones RN, Albert MS, Breitner JCS.

J Prev Alzheimers Dis. 2016;3(4):229-235. doi: 10.14283/jpad.2016.120.

32.

Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease.

Orban P, Madjar C, Savard M, Dansereau C, Tam A, Das S, Evans AC, Rosa-Neto P, Breitner JC, Bellec P; PREVENT-AD Research Group.

Sci Data. 2015 Oct 13;2:150043. doi: 10.1038/sdata.2015.43. eCollection 2015.

33.

Midlife adiposity predicts earlier onset of Alzheimer's dementia, neuropathology and presymptomatic cerebral amyloid accumulation.

Chuang YF, An Y, Bilgel M, Wong DF, Troncoso JC, O'Brien RJ, Breitner JC, Ferruci L, Resnick SM, Thambisetty M.

Mol Psychiatry. 2016 Jul;21(7):910-5. doi: 10.1038/mp.2015.129. Epub 2015 Sep 1.

34.

Comment: Yet another "disconnect" between amyloid and Alzheimer disease?

Breitner JC.

Neurology. 2015 Aug 25;85(8):698. doi: 10.1212/WNL.0000000000001871. Epub 2015 Jul 24. No abstract available.

PMID:
26208958
35.

Sleep-Wake Cycle Dysfunction in the TgCRND8 Mouse Model of Alzheimer's Disease: From Early to Advanced Pathological Stages.

Colby-Milley J, Cavanagh C, Jego S, Breitner JC, Quirion R, Adamantidis A.

PLoS One. 2015 Jun 15;10(6):e0130177. doi: 10.1371/journal.pone.0130177. eCollection 2015.

36.

Encouraging trends toward reduced risk of Alzheimer disease: What's good for the heart is good for the brain.

Breitner JCS, Galasko D.

Neurol Clin Pract. 2015 Jun;5(3):190-192. doi: 10.1212/CPJ.0000000000000110. No abstract available.

37.

Neuroinflammation in Alzheimer's disease.

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP.

Lancet Neurol. 2015 Apr;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5. Review.

38.

Alzheimer amyloid peptide aβ42 regulates gene expression of transcription and growth factors.

Barucker C, Sommer A, Beckmann G, Eravci M, Harmeier A, Schipke CG, Brockschnieder D, Dyrks T, Althoff V, Fraser PE, Hazrati LN, George-Hyslop PS, Breitner JC, Peters O, Multhaup G.

J Alzheimers Dis. 2015;44(2):613-24. doi: 10.3233/JAD-141902.

PMID:
25318543
39.

Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging.

Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P.

J Neuroinflammation. 2014 Jul 8;11:120. doi: 10.1186/1742-2094-11-120. Review.

40.

Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.

Poirier J, Miron J, Picard C, Gormley P, Théroux L, Breitner J, Dea D.

Neurobiol Aging. 2014 Sep;35 Suppl 2:S3-10. doi: 10.1016/j.neurobiolaging.2014.03.037. Epub 2014 May 15. Review.

41.

Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County Study.

Chuang YF, Breitner JCS, Chiu YL, Khachaturian A, Hayden K, Corcoran C, Tschanz J, Norton M, Munger R, Welsh-Bohmer K, Zandi PP; Cache County Investigators.

Neurobiol Aging. 2014 Nov;35(11):2429-2435. doi: 10.1016/j.neurobiolaging.2014.05.002. Epub 2014 May 9.

42.

Observations on DSM-5 Mild Neurocognitive Disorder vs. its predecessor, Mild Cognitive Impairment.

Breitner JC.

Acta Psychiatr Scand. 2015 Jan;131(1):15-7. doi: 10.1111/acps.12300. Epub 2014 Jun 9. No abstract available.

PMID:
24909394
43.

Mild cognitive impairment and progression to dementia: new findings.

Breitner JC.

Neurology. 2014 Jan 28;82(4):e34-5. doi: 10.1212/WNL.0000000000000158. No abstract available.

PMID:
24470608
44.

Three Cardinal Lessons from ADAPT - 10 Years on.

Breitner JCS, Lyketsos CG.

J Prev Alzheimers Dis. 2014;1(3):176-180. doi: 10.14283/jpad.2014.31.

PMID:
29251745
45.

An open science resource for establishing reliability and reproducibility in functional connectomics.

Zuo XN, Anderson JS, Bellec P, Birn RM, Biswal BB, Blautzik J, Breitner JC, Buckner RL, Calhoun VD, Castellanos FX, Chen A, Chen B, Chen J, Chen X, Colcombe SJ, Courtney W, Craddock RC, Di Martino A, Dong HM, Fu X, Gong Q, Gorgolewski KJ, Han Y, He Y, He Y, Ho E, Holmes A, Hou XH, Huckins J, Jiang T, Jiang Y, Kelley W, Kelly C, King M, LaConte SM, Lainhart JE, Lei X, Li HJ, Li K, Li K, Lin Q, Liu D, Liu J, Liu X, Liu Y, Lu G, Lu J, Luna B, Luo J, Lurie D, Mao Y, Margulies DS, Mayer AR, Meindl T, Meyerand ME, Nan W, Nielsen JA, O'Connor D, Paulsen D, Prabhakaran V, Qi Z, Qiu J, Shao C, Shehzad Z, Tang W, Villringer A, Wang H, Wang K, Wei D, Wei GX, Weng XC, Wu X, Xu T, Yang N, Yang Z, Zang YF, Zhang L, Zhang Q, Zhang Z, Zhang Z, Zhao K, Zhen Z, Zhou Y, Zhu XT, Milham MP.

Sci Data. 2014 Dec 9;1:140049. doi: 10.1038/sdata.2014.49. eCollection 2014.

46.

What should we do if we were wrong and Alzheimer was right?

Breitner JC.

Int Psychogeriatr. 2014 Jan;26(1):3-6. doi: 10.1017/S1041610213001749. Epub 2013 Oct 18. No abstract available.

PMID:
24135193
47.

Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study.

Peterson D, Munger C, Crowley J, Corcoran C, Cruchaga C, Goate AM, Norton MC, Green RC, Munger RG, Breitner JC, Welsh-Bohmer KA, Lyketsos C, Tschanz J, Kauwe JS; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 May;10(3):366-71. doi: 10.1016/j.jalz.2013.02.010. Epub 2013 May 30.

48.

Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.

Steinberg M, Hess K, Corcoran C, Mielke MM, Norton M, Breitner J, Green R, Leoutsakos J, Welsh-Bohmer K, Lyketsos C, Tschanz J.

Int J Geriatr Psychiatry. 2014 Feb;29(2):153-9. doi: 10.1002/gps.3980. Epub 2013 May 17.

49.

Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial.

Reckess GZ, Brandt J, Luis CA, Zandi P, Martin B, Breitner JC; ADAPT Research Group.

J Alzheimers Dis. 2013;36(3):433-43. doi: 10.3233/JAD-130113.

50.

Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study.

Peters ME, Rosenberg PB, Steinberg M, Norton MC, Welsh-Bohmer KA, Hayden KM, Breitner J, Tschanz JT, Lyketsos CG; Cache County Investigators.

Am J Geriatr Psychiatry. 2013 Nov;21(11):1116-24. doi: 10.1016/j.jagp.2013.01.049. Epub 2013 Feb 6.

Supplemental Content

Loading ...
Support Center